Adherex Technologies (NASDAQ:FENC) Issues Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Adherex Technologies (NASDAQ:FENC) issued its earnings results on Tuesday. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.03, Zacks reports. The firm had revenue of $17.87 million during the quarter, compared to the consensus estimate of $16.21 million. Adherex Technologies had a negative net margin of 6.09% and a negative return on equity of 6.93%.

Here are the key takeaways from Adherex Technologies’ conference call:

• PEDMARK net product sales rose 78% year over year to $17.1 million in Q2 2026, marking the company’s seventh consecutive quarter of growth. Non-GAAP adjusted EBITDA improved to $2.8 million from a $1.2 million loss a year ago.
• Commercial momentum accelerated, with Q2 demand up double digits sequentially, record patient enrollments and infusions, and a 280% increase in sales calls. July produced all-time highs for completed infusions, new enrollments, active patients, and new customers, while the expanded sales force now reaches roughly 5,000 targets.
• Medical and clinical efforts are expanding, including three actively accruing investigator-sponsored studies and an upcoming oral presentation of Japan’s STS-J01 trial data at SIOP 2026. Management said maturing data could support future label expansions and stronger NCCN recommendations, while discussions with potential Japanese and Asia-Pacific partners continue.
• Operating expenses excluding stock-based compensation increased to approximately $13.6 million, driven largely by higher commercial headcount and marketing investments. Management expects cash to decline in Q3 due to customer collection cycles, although it anticipates positive cash generation in Q4 and year-end cash.

Adherex Technologies Stock Performance

Adherex Technologies stock traded up $0.44 during mid-day trading on Thursday, reaching $12.27. 45,816 shares of the company were exchanged, compared to its average volume of 206,725. The firm has a market cap of $430.22 million, a PE ratio of -94.35 and a beta of 1.09. The firm’s 50-day simple moving average is $10.13 and its two-hundred day simple moving average is $8.57. Adherex Technologies has a twelve month low of $5.65 and a twelve month high of $13.25.

Analyst Upgrades and Downgrades

FENC has been the subject of several recent analyst reports. Zacks Research upgraded Adherex Technologies from a “strong sell” rating to a “hold” rating in a research note on Monday, May 25th. Wall Street Zen raised shares of Adherex Technologies from a “hold” rating to a “strong-buy” rating in a research report on Saturday, May 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Adherex Technologies in a research note on Friday, July 17th. B. Riley Financial reaffirmed a “buy” rating and set a $18.00 price target (up from $16.00) on shares of Adherex Technologies in a research report on Wednesday. Finally, HC Wainwright increased their price objective on Adherex Technologies from $13.00 to $16.00 and gave the company a “buy” rating in a report on Friday, May 22nd. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.40.

Hedge Funds Weigh In On Adherex Technologies

An institutional investor recently bought a new stake in Adherex Technologies stock. Jane Street Group LLC acquired a new position in shares of Adherex Technologies Inc. (NASDAQ:FENC) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 14,718 shares of the company’s stock, valued at approximately $90,000. Jane Street Group LLC owned 0.05% of Adherex Technologies at the end of the most recent reporting period. Hedge funds and other institutional investors own 55.51% of the company’s stock.

About Adherex Technologies

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc and changed its name to Fennec Pharmaceuticals Inc in September 2014. Fennec Pharmaceuticals Inc was founded in 1996 and is based in Research Triangle Park, North Carolina.